BeOne Medicines Ltd. – Sponsored ADR $ONC Shares Sold by Sei Investments Co.

Sei Investments Co. decreased its position in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 35.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,321 shares of the company’s stock after selling 2,336 shares during the quarter. Sei Investments Co.’s holdings in BeOne Medicines were worth $1,283,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of ONC. EFG International AG purchased a new stake in shares of BeOne Medicines in the 4th quarter valued at $25,000. Leonteq Securities AG purchased a new stake in BeOne Medicines during the fourth quarter worth about $35,000. Daiwa Securities Group Inc. acquired a new stake in shares of BeOne Medicines during the second quarter worth about $35,000. CWM LLC boosted its stake in shares of BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after purchasing an additional 39 shares during the period. Finally, Group One Trading LLC purchased a new position in shares of BeOne Medicines in the fourth quarter valued at approximately $61,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Wolfe Research reissued an “outperform” rating and issued a $370.00 price target on shares of BeOne Medicines in a research report on Monday. Citigroup reiterated an “outperform” rating on shares of BeOne Medicines in a research note on Thursday, August 6th. Wells Fargo & Company initiated coverage on BeOne Medicines in a research note on Monday, May 4th. They set an “overweight” rating and a $400.00 target price for the company. JPMorgan Chase & Co. increased their price target on BeOne Medicines from $415.00 to $425.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Finally, Morgan Stanley restated an “overweight” rating on shares of BeOne Medicines in a research note on Thursday, August 6th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, BeOne Medicines currently has an average rating of “Buy” and an average price target of $402.14.

BeOne Medicines Stock Up 0.1%

ONC stock opened at $359.27 on Wednesday. The stock has a market cap of $39.42 billion, a P/E ratio of 63.25 and a beta of 0.49. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $253.95 and a twelve month high of $385.22. The company’s 50 day moving average is $299.80 and its two-hundred day moving average is $308.98.

BeOne Medicines (NASDAQ:ONC) last posted its earnings results on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.65. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. The firm had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.66 billion. Research analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 7.3 earnings per share for the current fiscal year.

Insider Activity

In related news, COO Xiaobin Wu sold 1,484 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $269.37, for a total transaction of $399,745.08. Following the transaction, the chief operating officer owned 40 shares in the company, valued at $10,774.80. This trade represents a 97.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Oyler sold 145,861 shares of the business’s stock in a transaction that occurred on Tuesday, July 14th. The shares were sold at an average price of $305.95, for a total value of $44,626,172.95. Following the completion of the sale, the chief executive officer owned 8,122 shares of the company’s stock, valued at approximately $2,484,925.90. This represents a 94.73% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 345,229 shares of company stock worth $105,522,788. Corporate insiders own 6.19% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.